Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 3:36 a.m.

    📋 RALLYBIO CORPORATION (RLYB) - Clinical Trial Update

    Filing Date: 2022-06-02

    Accepted: 2022-06-02 09:00:55

    Event Type: Clinical Trial Update

    Event Details:

    Rallybio Corporation (RLYB) Announces Clinical Trial Update Rallybio Corporation (RLYB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: years, search
    • Diseases/Conditions: helping to create, its next Chief Financial Officer-- NEW HAVEN
    • Collaboration: Rallybio

    🔬 Clinical Development Pipeline (RALLYBIO CORPORATION):

    Product Type Development Stage Therapeutic Area Source
    RLYB116 for Injection DRUG Phase PHASE1 Hematologic Diseases ClinicalTrials.gov
    Clinical data collection OTHER Preclinical Fetal and Neonatal Alloimmune Thrombocytopenia ClinicalTrials.gov
    Anti-(integrin beta-3) human monoclonal antibody DRUG Phase PHASE2 Fetal and Neonatal Alloimmune Thrombocytopenia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Rallybio Corporation
    • CIK: 0001739410
    • Ticker Symbol: RLYB
    • Period End Date: 2022-06-02
    • Document Type: 8-K

Search

News categories